Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476189 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
A Phase 1 study of Healthy Subjects, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01476189: Completed Phase 1 study of Healthy Subjects, sponsored by GlaxoSmithKline.
NCT01476189 is a Phase 1 study of Healthy Subjects that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476189, a Phase 1 study of Healthy Subjects, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
A repeat dose pharmacokinetic study investigating two paracetamol formulations
Conditions Studied
Interventions
- DRUG Experimental paracetamol formulation
- DRUG Marketed paracetamol
- DRUG Higher dose marketed paracetamol
Study Locations (1)
Nebraska
- MDS Pharma Services NEBRASKA - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2009-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
What the finished NCT01476189 record still lists
NCT01476189 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 3 interventions - of which Experimental paracetamol formulation is the first listed.
NCT01476189 reports a single indexed study location in Nebraska.
Frequently Asked Questions
What is clinical trial NCT01476189 about?
NCT01476189 is a clinical study titled "A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations". A repeat dose pharmacokinetic study investigating two paracetamol formulations
What is the current status of trial NCT01476189?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2009-11. Estimated completion is 2009-12.
What conditions does trial NCT01476189 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT01476189?
The interventions under investigation include: Experimental paracetamol formulation (DRUG), Marketed paracetamol (DRUG), Higher dose marketed paracetamol (DRUG).
Who is sponsoring clinical trial NCT01476189?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01476189 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01476189's enrollment target sits among peer trials
28 42nd of 69 higher than 26 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
-
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia